SLS · SELLAS Life Sciences Group Inc. Common Stock
View on chartInsiders & Stakes
| Stergiou Angelos M. President and CEO | ▲ Buy | Grant | 1,759,183 Shares held | 6/16/2026 | View profile |
| CICIC DRAGAN SVP, Chief Development Officer | ▲ Buy | Grant | 557,805 Shares held | 1/7/2026 | View profile |
| Burns John Thomas VP, Finance & Corp Controller | ▲ Buy | Grant | 554,327 Shares held | 1/7/2026 | View profile |
| Kalin Katherine Bach Director | ▲ Buy | Grant | 154,400 Shares held | 1/7/2026 | View profile |
| WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | ▲ Buy | Grant | 117,225 Shares held | 1/22/2024 | View profile |
| Wasman Jane Director | ▲ Buy | Grant | 92,900 Shares held | 1/7/2026 | View profile |
| VAN NOSTRAND ROBERT L Director | ▲ Buy | Grant | 82,900 Shares held | 1/7/2026 | View profile |
| SCHEINBERG DAVID A Director | ▲ Buy | Grant | 73,082 Shares held | 1/7/2026 | View profile |
| Varian John Director | ▲ Buy | Grant | 72,900 Shares held | 1/7/2026 | View profile |
| Francomano Robert Chief Commercial Officer | ▲ Buy | Grant | 40,918 Shares held | 1/22/2024 | View profile |
Transaction History
| Stergiou Angelos M. | ▲ Buy | Grant | 1,065,000 | $0 | 6/16/2026 |
| Wasman Jane | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 |
| Burns John Thomas | ▲ Buy | Grant | 300,000 | $0 | 1/7/2026 |
| SCHEINBERG DAVID A | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 |
| Varian John | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 |
| CICIC DRAGAN | ▲ Buy | Grant | 300,000 | $0 | 1/7/2026 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 |
| Kalin Katherine Bach | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 |
| CICIC DRAGAN | ▼ Sell | Other | 63,800 | $96K | 12/3/2025 |
| Stergiou Angelos M. | ▼ Sell | Other | 187,066 | $281K | 12/3/2025 |
| Burns John Thomas | ▼ Sell | Other | 58,592 | $88K | 12/3/2025 |
| Kalin Katherine Bach | ▲ Buy | Open Market | 63,400 | $101K | 11/19/2025 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Open Market | 10,000 | $15K | 6/12/2025 |
| Wasman Jane | ▲ Buy | Open Market | 20,000 | $34K | 5/30/2025 |
| Kalin Katherine Bach | ▲ Buy | Open Market | 20,000 | $36K | 5/22/2025 |
| SCHEINBERG DAVID A | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 |
| Stergiou Angelos M. | ▲ Buy | Grant | 243,900 | $0 | 1/10/2025 |
| Stergiou Angelos M. | ▲ Buy | Grant | 257,000 | $0 | 1/10/2025 |
| Wasman Jane | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 |
| Kalin Katherine Bach | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 |
| Varian John | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 |
| CICIC DRAGAN | ▲ Buy | Grant | 113,000 | $0 | 1/10/2025 |
| CICIC DRAGAN | ▲ Buy | Grant | 81,300 | $0 | 1/10/2025 |
| Burns John Thomas | ▲ Buy | Grant | 113,000 | $0 | 1/10/2025 |
| Burns John Thomas | ▲ Buy | Grant | 81,300 | $0 | 1/10/2025 |
| Stergiou Angelos M. | ▼ Sell | Other | 28,289 | $32K | 12/4/2024 |
| CICIC DRAGAN | ▼ Sell | Other | 8,256 | $9K | 12/4/2024 |
| Burns John Thomas | ▼ Sell | Other | 7,165 | $8K | 12/4/2024 |
| SCHEINBERG DAVID A | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 |
| WOOD BARBARA A | ▲ Buy | Grant | 35,000 | $0 | 1/22/2024 |
| Wasman Jane | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 |
| Kalin Katherine Bach | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 |
| Francomano Robert | ▲ Buy | Grant | 20,000 | $0 | 1/22/2024 |
| Varian John | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 |
| Stergiou Angelos M. | ▲ Buy | Grant | 159,000 | $0 | 1/22/2024 |
| Burns John Thomas | ▲ Buy | Grant | 47,000 | $0 | 1/22/2024 |
| WOOD BARBARA A | ▼ Sell | Other | 4,119 | $4K | 12/6/2023 |
| Francomano Robert | ▼ Sell | Other | 1,082 | $1K | 12/6/2023 |
| Stergiou Angelos M. | ▼ Sell | Other | 12,268 | $13K | 12/6/2023 |
| Burns John Thomas | ▼ Sell | Other | 2,929 | $3K | 12/6/2023 |
| WOOD BARBARA A | ▲ Buy | Grant | 20,000 | $0 | 2/2/2023 |
| Stergiou Angelos M. | ▲ Buy | Grant | 58,000 | $0 | 2/2/2023 |
| Francomano Robert | ▲ Buy | Grant | 12,000 | $0 | 2/2/2023 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 |
| Kalin Katherine Bach | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 |
| SCHEINBERG DAVID A | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 |
| Wasman Jane | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 |
| Burns John Thomas | ▲ Buy | Grant | 20,000 | $0 | 2/2/2023 |
| Varian John | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 |
| Stergiou Angelos M. | ▼ Sell | Open Market | 6,494 | $17K | 12/5/2022 |
| Burns John Thomas | ▼ Sell | Open Market | 1,159 | $3K | 12/5/2022 |
| WOOD BARBARA A | ▼ Sell | Open Market | 2,153 | $6K | 12/5/2022 |
| VAN NOSTRAND ROBERT L | ▲ Buy | Grant | 1,900 | $0 | 1/31/2022 |
| SCHEINBERG DAVID A | ▲ Buy | Grant | 1,900 | $0 | 1/31/2022 |
| Burns John Thomas | ▲ Buy | Grant | 9,600 | $0 | 1/31/2022 |
| Wasman Jane | ▲ Buy | Grant | 1,900 | $0 | 1/31/2022 |
| Varian John | ▲ Buy | Grant | 1,900 | $0 | 1/31/2022 |
| WOOD BARBARA A | ▲ Buy | Grant | 13,000 | $0 | 1/31/2022 |
| Stergiou Angelos M. | ▲ Buy | Grant | 44,000 | $0 | 1/31/2022 |
| Stergiou Angelos M. | ▼ Sell | Open Market | 2,120 | $13K | 12/2/2021 |
| Burns John Thomas | ▼ Sell | Open Market | 231 | $1K | 12/2/2021 |
| WOOD BARBARA A | ▼ Sell | Open Market | 847 | $5K | 12/2/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.